Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2025
Date Filed: April 29, 2025
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate governance updates rather than financial performance.
Material Changes
The primary material change disclosed in this filing is the submission of three "Change of Director's Interest Notice" exhibits (Exhibit 99.1). No other material changes to operations or financial status are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate exhibits regarding director interests into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the three "Change of Director's Interest Notice" exhibits referenced but not included in the text.
- Confirm the impact of these director interest changes on the company's governance structure.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital raising activities.